{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-025506","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.186130+00:00","generated_at":"2026-06-17T08:44:30.518887+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Emmaus Life Sciences reports FY2022 net loss of $10.6M; going concern doubt raised","bullets":["Net revenues $18.4M, down 10.7% from $20.6M in 2021; operating loss widened to $6.6M from $6.1M.","Net loss attributable to common stockholders $10.6M ($0.21 per share) vs $15.9M ($0.32) in 2021.","Cash and cash equivalents $2.0M at Dec 31, 2022, down from $2.3M; substantial doubt about going concern.","Audit report includes going-concern qualification; company cites Covid disruptions and higher distributor discounts.","Marketing authorizations for Endari obtained in Qatar, Kuwait, and UAE in 2022; management cites strong sales momentum."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-025506","json":"https://secwatch.observer/filing/0001213900-23-025506.json","markdown":"https://secwatch.observer/filing/0001213900-23-025506.md","text":"https://secwatch.observer/filing/0001213900-23-025506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390023025506/0001213900-23-025506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390023025506/ea176042-8k_emmauslife.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:44:30.518887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f03ae0d0984c954ce9993ad340cdc6fa7bdabbb4","claim":"Emmaus Life Sciences, Inc. reported the year ended December 31, 2022 results: revenue $18.4 million, net income ($10.6 million, or $0.21 per share), EPS $(0.21) per share.","evidence_excerpt":"earlier in 2022, so the sales momentum is strong for the upcoming year.” Financial and Operating Results Net Revenues. Net revenues for the year ended December 31, 2022 were $18.4 million, compared to $20.6 million for 2021. Although sales volume as measured by number of boxes of Endari sold increased compared to 2021, net revenues were adversely affected by","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390023025506/0001213900-23-025506-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$18.4 million"},{"label":"Net income","value":"($10.6 million, or $0.21 per share)"},{"label":"EPS","value":"$(0.21) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}